Vitrolife AB (publ) (VITR.ST)
SEK 214.4
(1.13%)
SEK 214.4
(1.13%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -3.58 Billion SEK | 12.08% |
| 2022 | 654 Million SEK | 50.21% |
| 2021 | 435.37 Million SEK | 17.67% |
| 2020 | 370.01 Million SEK | -24.17% |
| 2019 | 487.94 Million SEK | 23.87% |
| 2018 | 393.91 Million SEK | 15.57% |
| 2017 | 340.85 Million SEK | 36.98% |
| 2016 | 248.84 Million SEK | 10.04% |
| 2015 | 226.13 Million SEK | 57.75% |
| 2014 | 143.34 Million SEK | 78.3% |
| 2013 | 80.39 Million SEK | 61.69% |
| 2012 | 49.72 Million SEK | 21.53% |
| 2011 | 40.91 Million SEK | 23.77% |
| 2010 | 33.06 Million SEK | 8.72% |
| 2009 | 30.4 Million SEK | 12.1% |
| 2008 | 27.12 Million SEK | 28.96% |
| 2007 | 21.03 Million SEK | 5.03% |
| 2006 | 20.02 Million SEK | 66.14% |
| 2005 | 12.05 Million SEK | -7.58% |
| 2004 | 13.04 Million SEK | -68.85% |
| 2003 | 41.87 Million SEK | -65.79% |
| 2002 | 122.41 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 238 Million SEK | 48.75% |
| 2024 Q1 | 160 Million SEK | -17.95% |
| 2024 Q3 | 174 Million SEK | -26.89% |
| 2023 FY | 733 Million SEK | 12.08% |
| 2023 Q1 | 159 Million SEK | -5.36% |
| 2023 Q2 | 188 Million SEK | 18.24% |
| 2023 Q3 | 179 Million SEK | -4.79% |
| 2023 Q4 | 195 Million SEK | 8.94% |
| 2022 Q2 | 175 Million SEK | 31.58% |
| 2022 Q1 | 133 Million SEK | 236.1% |
| 2022 Q3 | 177 Million SEK | 1.14% |
| 2022 Q4 | 168 Million SEK | -5.08% |
| 2022 FY | 654 Million SEK | 50.21% |
| 2021 Q1 | 142.47 Million SEK | -3.29% |
| 2021 Q2 | 111.14 Million SEK | -21.99% |
| 2021 Q4 | 39.57 Million SEK | -72.17% |
| 2021 FY | 435.37 Million SEK | 17.67% |
| 2021 Q3 | 142.18 Million SEK | 27.93% |
| 2020 Q4 | 147.33 Million SEK | 30.99% |
| 2020 FY | 370.01 Million SEK | -24.17% |
| 2020 Q2 | 16.41 Million SEK | -82.51% |
| 2020 Q3 | 112.47 Million SEK | 585.38% |
| 2020 Q1 | 93.8 Million SEK | -28.39% |
| 2019 Q3 | 130.47 Million SEK | 6.13% |
| 2019 Q4 | 131 Million SEK | 0.4% |
| 2019 Q2 | 122.93 Million SEK | 18.74% |
| 2019 FY | 487.94 Million SEK | 23.87% |
| 2019 Q1 | 103.53 Million SEK | 1.77% |
| 2018 Q4 | 101.73 Million SEK | -2.22% |
| 2018 Q2 | 98.48 Million SEK | 9.83% |
| 2018 Q3 | 104.03 Million SEK | 5.64% |
| 2018 Q1 | 89.66 Million SEK | 0.39% |
| 2018 FY | 393.91 Million SEK | 15.57% |
| 2017 Q4 | 89.31 Million SEK | 10.12% |
| 2017 FY | 340.85 Million SEK | 36.98% |
| 2017 Q2 | 94.6 Million SEK | 20.81% |
| 2017 Q1 | 78.31 Million SEK | -0.05% |
| 2017 Q3 | 81.1 Million SEK | -14.27% |
| 2016 Q3 | 56.69 Million SEK | -8.23% |
| 2016 FY | 248.84 Million SEK | 10.04% |
| 2016 Q1 | 52.01 Million SEK | -25.67% |
| 2016 Q2 | 61.78 Million SEK | 18.76% |
| 2016 Q4 | 78.34 Million SEK | 38.2% |
| 2015 FY | 226.13 Million SEK | 57.75% |
| 2015 Q4 | 69.98 Million SEK | 5.73% |
| 2015 Q1 | 39.45 Million SEK | 9.28% |
| 2015 Q2 | 50.5 Million SEK | 28.01% |
| 2015 Q3 | 66.19 Million SEK | 31.06% |
| 2014 Q2 | 33.6 Million SEK | 12.31% |
| 2014 Q1 | 29.92 Million SEK | 37.73% |
| 2014 FY | 143.34 Million SEK | 78.3% |
| 2014 Q4 | 36.1 Million SEK | -17.42% |
| 2014 Q3 | 43.71 Million SEK | 30.1% |
| 2013 FY | 80.39 Million SEK | 61.69% |
| 2013 Q2 | 18.63 Million SEK | 9.91% |
| 2013 Q1 | 16.95 Million SEK | 39.73% |
| 2013 Q3 | 23.08 Million SEK | 23.88% |
| 2013 Q4 | 21.72 Million SEK | -5.9% |
| 2012 FY | 49.72 Million SEK | 21.53% |
| 2012 Q3 | 14.64 Million SEK | 15.4% |
| 2012 Q4 | 12.13 Million SEK | -17.12% |
| 2012 Q1 | 15.11 Million SEK | 295.03% |
| 2012 Q2 | 12.68 Million SEK | -16.04% |
| 2011 Q1 | 10.13 Million SEK | 19.12% |
| 2011 FY | 40.91 Million SEK | 23.77% |
| 2011 Q4 | 3.82 Million SEK | -73.37% |
| 2011 Q3 | 14.36 Million SEK | 14.06% |
| 2011 Q2 | 12.59 Million SEK | 24.25% |
| 2010 Q1 | 10 Million SEK | 50.94% |
| 2010 Q2 | 8.67 Million SEK | -13.25% |
| 2010 Q3 | 5.87 Million SEK | -32.35% |
| 2010 Q4 | 8.5 Million SEK | 44.92% |
| 2010 FY | 33.06 Million SEK | 8.72% |
| 2009 FY | 30.4 Million SEK | 12.1% |
| 2009 Q2 | 7.79 Million SEK | 0.0% |
| 2009 Q4 | 6.62 Million SEK | -7.89% |
| 2009 Q3 | 7.19 Million SEK | -7.67% |
| 2008 FY | 27.12 Million SEK | 28.96% |
| 2007 FY | 21.03 Million SEK | 5.03% |
| 2006 FY | 20.02 Million SEK | 66.14% |
| 2005 FY | 12.05 Million SEK | -7.58% |
| 2004 FY | 13.04 Million SEK | -68.85% |
| 2003 FY | 41.87 Million SEK | -65.79% |
| 2002 FY | 122.41 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.55 Million SEK | -4527.803% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 1293.945% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 1293.945% |
| Arcoma AB | 4.66 Million SEK | 77117.167% |
| Bactiguard Holding AB (publ) | -131.93 Million SEK | -2620.32% |
| BICO Group AB (publ) | -618.3 Million SEK | -480.463% |
| Boule Diagnostics AB (publ) | 39.27 Million SEK | 9239.292% |
| CellaVision AB (publ) | 167.05 Million SEK | 2248.446% |
| Clinical Laserthermia Systems AB (publ) | -65.93 Million SEK | -5343.405% |
| Chordate Medical Holding AB (publ) | -29.57 Million SEK | -12036.656% |
| C-Rad AB (publ) | 44.24 Million SEK | 8211.834% |
| Duearity AB (publ) | -25.76 Million SEK | -13830.831% |
| Dignitana AB (publ) | -15.02 Million SEK | -23785.266% |
| Episurf Medical AB (publ) | -94.8 Million SEK | -3685.865% |
| Getinge AB (publ) | 3.81 Billion SEK | 194.101% |
| Scandinavian Real Heart AB (Publ) | -68.44 Million SEK | -5143.559% |
| Iconovo AB (publ) | -45.77 Million SEK | -7740.222% |
| Integrum AB (publ) | 6.51 Million SEK | 55210.759% |
| Luxbright AB (publ) | -25.8 Million SEK | -13808.459% |
| Mentice AB (publ) | -679 Thousand SEK | -528471.429% |
| OssDsign AB (publ) | -91.95 Million SEK | -3802.954% |
| Paxman AB (publ) | 12.61 Million SEK | 28541.239% |
| Promimic AB (publ) | -9.11 Million SEK | -39261.702% |
| Qlife Holding AB (publ) | -168.69 Million SEK | -2027.483% |
| SciBase Holding AB (publ) | -53.93 Million SEK | -6553.813% |
| ScandiDos AB (publ) | -13.48 Million SEK | -26518.705% |
| Sectra AB (publ) | 518.49 Million SEK | 792.201% |
| Sedana Medical AB (publ) | -65.54 Million SEK | -5375.46% |
| Senzime AB (publ) | -133.74 Million SEK | -2583.465% |
| SpectraCure AB (publ) | -21.35 Million SEK | -16709.517% |
| Stille AB | 44.95 Million SEK | 8084.072% |
| Xvivo Perfusion AB (publ) | 38.5 Million SEK | 9420.625% |